Authorities canceled an invite-only "Peptide Party" planned in Bengaluru for August 29, according to The Indian Express, which reports the event drew more than 200 registrations for around 50 places. The gathering is gone, the demand behind it is not.

Peptides are short chains of amino acids, smaller than proteins. Some, like insulin and semaglutide, are established prescription medicines made in regulated facilities, while others named in the report, BPC-157, TB-500, epitalon and MOTS-c, are sold openly by "research chemical" suppliers, sometimes shipped as injectable vials to homes without a prescription.

Borrowed credibility

That gap is the whole story. Dr Anoop Misra, Executive Chairman of Fortis C-DOC for Diabetes and Allied Sciences, told the paper that the word peptide "can sound reassuring because some of the world's most successful modern medicines are peptides," but that "scientific credibility does not automatically extend from semaglutide or insulin to every compound sold online under the same broad label."

For semaglutide and tirzepatide, the report says benefits are supported by large, well-designed clinical trials. For most of what is being marketed for recovery, sleep, anti-aging and longevity, the honest answer given is that we do not know, because the claims rest on animal studies, laboratory findings, theoretical mechanisms or anecdote.

What is actually in the vial

The supply-chain detail is the part buyers skip. Testing of some peptides obtained online in Belgium found contamination with toxic heavy metals including arsenic and lead, and a US laboratory specializing in these products found a proportion of samples did not match their labels for purity or quantity.

Peptides are also fragile, and the article notes that poor storage or temperature control in transit means a product may deteriorate before it arrives. "Research chemical" is a label, not a safety certification, and the report frames it as a regulatory workaround used while marketing clearly encourages human use.

Where the regulators are

In July 2026, the US FDA recommended against adding BPC-157 to the 503A compounding list, citing a lack of adequate human evidence on safety and effectiveness. Non-clinical evaluations raised concerns including blood-clotting abnormalities and liver changes in animal studies, plus inconsistent quality between batches.

Bottom line

A canceled party is a symptom, not the disease. The report's position is that the market has outrun both the evidence and the oversight, and that anecdote shared at scale still is not clinical data.